MDXH vs. XGN, SERA, BDSX, OPGN, BNR, ENZ, BGLC, ACON, NTRA, and LH
Should you be buying MDxHealth stock or one of its competitors? The main competitors of MDxHealth include Exagen (XGN), Sera Prognostics (SERA), Biodesix (BDSX), OpGen (OPGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioNexus Gene Lab (BGLC), Aclarion (ACON), Natera (NTRA), and Laboratory Co. of America (LH). These companies are all part of the "medical laboratories" industry.
MDxHealth vs.
Exagen (NASDAQ:XGN) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
75.3% of Exagen shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Exagen has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
In the previous week, Exagen had 1 more articles in the media than MDxHealth. MarketBeat recorded 7 mentions for Exagen and 6 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.23 beat Exagen's score of 0.09 indicating that MDxHealth is being referred to more favorably in the news media.
Exagen received 13 more outperform votes than MDxHealth when rated by MarketBeat users. Likewise, 62.22% of users gave Exagen an outperform vote while only 55.56% of users gave MDxHealth an outperform vote.
Exagen has higher earnings, but lower revenue than MDxHealth. Exagen is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Exagen has a net margin of -30.36% compared to MDxHealth's net margin of -49.52%. Exagen's return on equity of -92.58% beat MDxHealth's return on equity.
Exagen currently has a consensus price target of $7.50, suggesting a potential upside of 13.64%. MDxHealth has a consensus price target of $6.50, suggesting a potential upside of 218.63%. Given MDxHealth's higher possible upside, analysts clearly believe MDxHealth is more favorable than Exagen.
Summary
Exagen beats MDxHealth on 12 of the 17 factors compared between the two stocks.
Get MDxHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MDxHealth Competitors List
Related Companies and Tools
This page (NASDAQ:MDXH) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy MDXH Stock Free MDXH Stock Alerts